^
    23h
    A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, BioLite, Inc. | Trial completion date: Jun 2028 --> Dec 2028 | Trial primary completion date: Dec 2027 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    azacitidine
    3d
    CMML2AML: machine-learning discovery of co-mutations and specific single mutations predictive of blast transformation in chronic myelomonocytic leukemia. (PubMed, Blood Cancer J)
    The prognostic relevance of "NRAS + SETBP1", "ASXL1 + RUNX1", NPM1 and BCOR was validated in an external cohort from Italy (N = 501). Taken together, these observations highlight i) the possibility of prognostic interaction of mutations in CMML that should be considered in the development of future risk models and ii) the distinct genotypic and prognostic characteristics of NPM1-mutated CMML.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • SETBP1 (SET Binding Protein 1) • PHF6 (PHD Finger Protein 6)
    |
    NPM1 mutation • ASXL1 mutation
    7d
    Pathogenic TET2 Variants and Autoinflammatory Manifestations in Myeloid Hematologic Malignancies: Case Report and Literature Review. (PubMed, Eur J Rheumatol)
    Despite initial treatment with corticosteroids and diuretics, her condition worsened, which led to the need to implement treatment with colchicine and anakinra. Eur J Rheumatol. 2026, 13(1), 0119, doi:10.5152/eurjrheum.2026.24119.
    Journal
    |
    TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    Kineret (anakinra)
    8d
    MYELOMONO-3: Cohort of Patients With Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P=N/A, N=5000, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris
    New trial
    12d
    NCI-2020-14163: Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=44 --> 24
    Enrollment closed • Enrollment change
    |
    TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SETBP1 (SET Binding Protein 1)
    |
    TP53 mutation • NRAS mutation • ASXL1 mutation
    |
    azacitidine • seclidemstat (SP2577)
    13d
    Successful Haplo-Hematopoietic Stem Cell Transplantation for Juvenile Myelomonocytic Leukemia in a Child With Underlying Thrombocytopenia-Absent Radius Syndrome: A Unique Case. (PubMed, Cancer Rep (Hoboken))
    This case represents, to our knowledge, one of the very few-if not the first-reported instances of successful HSCT for JMML in a patient with TAR syndrome. It underscores the importance of vigilant surveillance in TAR patients for potential malignant transformation and demonstrates the curative potential of HSCT in rare congenital-hematologic overlap syndromes.
    Journal
    |
    NF1 (Neurofibromin 1) • RBM8A (RNA Binding Motif Protein 8A)
    |
    RAS mutation
    |
    cyclophosphamide • melphalan • Grafapex (treosulfan)
    14d
    A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. (PubMed, Leuk Lymphoma)
    Lower-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are commonly managed with erythropoiesis-stimulating agents, luspatercept, or hypomethylating agents. There were no dose-limiting toxicities. Although safe, fostamatinib demonstrated no clinical benefit, underscoring the need for alternative strategies to modulate inflammatory signaling in MDS/CMML.
    P1 data • Journal
    |
    SYK (Spleen tyrosine kinase)
    |
    Reblozyl (luspatercept-aamt) • Tavalisse (fostamatinib)
    14d
    Low-dose decitabine increases peripheral NKT-like cell proportions in patients with chronic myeloid neoplasms. (PubMed, Cancer Pathog Ther)
    Among the three patients who received at least three cycles of decitabine, improvements in anemia and thrombocytopenia were observed in those with elevated NKT-like cell levels. These findings suggest that low-dose decitabine may enhance the NKT-like cell population, which may be associated with therapeutic responses in chronic myeloid neoplasms.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    decitabine
    18d
    M-HArbOr: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (clinicaltrials.gov)
    P1, N=18, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    azacitidine • Ojjaara (momelotinib)
    18d
    BRAF Mutations in Myeloid Neoplasms: Prevalence, Co-Mutation Landscape, and Clinical Outcomes-A Comprehensive Review. (PubMed, Biomedicines)
    BRAF mutations in myeloid neoplasms are rare, heterogeneous, and usually represent secondary events in clonal evolution. Although mutation clearance appears prognostically relevant, current targeted approaches provide limited durability, underscoring the need for prospective studies in this setting.
    Clinical data • Review • Journal
    |
    BRAF (B-raf proto-oncogene) • DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2)
    |
    BRAF V600E • BRAF mutation • RAS mutation • ASXL1 mutation • SRSF2 mutation
    21d
    Impact of High Serum Lysozyme Activity on Renal Function and Survival Outcomes in Transplant-Eligible and Ineligible Acute Myeloid Leukemia. (PubMed, Cancer Med)
    After remission induction, most patients with high-lysozyme levels showed creatinine level recovery (AML onset: median 1.15 mg/dL, 1 month later: median 0.72 mg/dL, 3 months later: median 0.65 mg/dL). The effect of lysozyme levels on prognosis is limited because renal function recovers in many patients with high-lysozyme levels after chemotherapy.
    Retrospective data • Journal
    |
    LYZ (Lysozyme 2)